Since its creation in 2000, Gavi and its partners have made significant strides in delivering cost-effective vaccines around the world. Yet, a rapidly changing global landscape—marked by rapid urbanization, increasing vaccine hesitancy, and protracted displacement—is impeding global vaccination efforts. Immunization coverage rates remain highly variable, and in some cases far below levels required for sustained public health impact.
The COVID-19 pandemic further exacerbated these challenges, leading to historic backsliding on routine immunization and a resurgence in vaccine-preventable diseases. Current macroeconomic conditions are constraining foreign aid budgets and squeezing health care budgets in low- and middle-income countries, alike.
While Gavi’s mission—to save lives and protect people's health by increasing equitable and sustainable use of vaccines—remains highly relevant, there is also a need to continue to adapt its model to deliver health impact and value for money.
Against this backdrop, CGD has conducted research and analysis on priorities and policy options for Gavi, leveraging expertise in technical areas such as cost-effectiveness, value for money, and procurement, alongside extensive knowledge of the global health and broader development finance landscapes. In 2019, CGD produced a comprehensive report on Gavi’s future in the lead up to the 2021–2025 strategic period, known as “Gavi 5.0”. Building on this, CGD experts are currently providing analysis and commentary to inform Gavi’s board and leadership, as well as the broader global health community, on priorities and areas for reform for Gavi’s next strategic period, “Gavi 6.0”.
Explore our proposals for Gavi 6.0
